Skip to main content

Table 1 Preclinical properties of the tau-specific PET tracers

From: Tau PET imaging: present and future directions

  

PBB3

THK5117

THK5351

AV-1451

Radiotracer

 

11C

cold

18F

3H

18F

18F

3H

In vitro binding

Brain tissue

Kd1 = 2.5 [28]

Bmax1 = 25nM [28]

Kd2 = 100 [28]

Bmax2 = 300nM [28]

 

Kd = 5.19 [15]; 11.5 [14]

Bmax = 338 [15]

Kd1 = 2.2a; 3.1b [24]

Kd2 = 23.6a; 34.6b [24]

Bmax1 = 250a; 250b [24]

Bmax2 = 1416a; 1226b [24]

Kd = 2.9 [26]

Bmax = 368.3 [26]

15f [22]

Kd = 1.4–3.72c; 0.63–1.70d [23]

Bmax = 15–62.5nMc;

46.9–119.7nMd [23]

Ki

Ki1 = 1.3b; 5.9e [33]

Ki2 = 23.5b [33]

Ki1 = 0.001a; 0.0005b [24]

Ki2 = 27.4 [14]; 16a [24]; 10.5 [15]

Ki3 = 750a; 800b [24]

   

Ki1 = 0.3b; 3.3e [33]

Ki2 = 97.2b [33]

 

Ex vivo biodistribution

LogP

  

2.32 [15]

 

1.5 [26]

 

1.67 [18]

Uptake in mouse brain (2 min)

  

6.06%ID/g [15]

 

4.36%ID/g [26]

7.5%ID/g [29]

 
  1. aTissue from hippocampal region; btissue from temporal region; ctissue from frontal cortex; dtissue from entorhinal cortex; etissue from motor cortex in a case of progressive supranuclear palsy; fdetermined by autoradiography. Aβ beta-amyloid, Bmax receptor density, ID injected dose, Kd dissociation constant, Ki binding affinity, LogP partition coefficient. Ki and Kd values in nM and Bmax values in pmol/g (unless stated otherwise)